Search for: "Aparajita Lath"
Results 1 - 20
of 21
Sorted by Relevance
|
Sort by Date
22 Sep 2022, 5:25 am
Aparajita Lath is a Master of Laws student (LLM 2023). [read post]
21 May 2013, 3:03 am
Aparajita Lath - SpicyIP BloggerTake a good hard look at the photograph on the right. [read post]
29 Jan 2013, 10:44 am
Aparajita Lath, another applicant, started her fellowship contention strongly with an incisive post on business method patents, the manner in which they are still being granted in India subverting the express statutory exclusion of the same and the policy considerations involved therein. [read post]
11 Feb 2013, 7:52 pm
The week began with a two part post by Aparajita Lath on the impact of the digitization of content on the television, film and music industries. [read post]
2 Apr 2013, 10:33 am
Aparajita Lath wrote about the reference (order available here) made to a Full Bench of the Delhi High Court under the case Reckitt Benkiser India Ltd. v. [read post]
18 Nov 2022, 5:00 am
By Aparajita Lath The Truth Pill, authored by Dinesh Thakur and Prashant Reddy, is a monumental work that convincingly shows that drug regulation is but a myth in India. [read post]
18 Mar 2013, 3:12 am
Aparajita Lath wrote an extensive post on the copyright controversy surrounding the movie remake of Zanjeer. [read post]
22 Jan 2013, 1:10 pm
Aparajita Lath, a 3rd year student from NUJS, brings us this incisive guest post on Business Method Patents in India. [read post]
24 Jan 2013, 5:00 pm
Aparajita Lath brings us her third submission to our SpicyIP Fellowship applicant series. [read post]
26 Jun 2023, 6:59 am
By Aparajita Lath For over 100 years, policy makers and pharmaceutical manufacturers in the U.S. have debated whether the government should produce drugs and biologics. [read post]
7 Feb 2023, 10:28 am
By Aparajita Lath In January, the Federal Trade Commission (FTC) released a new draft rule that would categorically ban non-compete clauses — contractual terms between an employer and an employee that prevent subsequent employment at a competing firm — across the country. [read post]
13 Mar 2023, 5:00 am
By Aparajita Lath When it comes to health-related consumer purchases, buyers surely need to beware. [read post]
12 Jan 2023, 8:14 am
By Aparajita Lath Last month, the patent battle between COVID-19 mRNA vaccine manufacturers continued with BioNTech/Pfizer filing a strong defense and counter-claim to Moderna’s allegations of patent infringement. [read post]
22 Dec 2023, 5:00 am
By Aparajita Lath* The World Health Organization (WHO), in collaboration with the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO), hosted the 10thTrilateral Symposium on Human Health and Climate Change in Geneva this November. [read post]
22 Nov 2022, 8:43 am
By Aparajita Lath The future of public health in an “RNA world” is on trial in a trade secrecy dispute worth $950 million currently being fought before the District Court of the Western District of Washington, Seattle between HDT Bio Corp. and Emcure Pharmaceuticals. [read post]
30 Sep 2022, 12:40 pm
By Aparajita Lath Indian lawmakers are currently debating proposed amendments that would make it easier for foreign investors to research and develop products from native biological resources, such as plants. [read post]
31 Oct 2022, 5:00 am
By Aparajita Lath Some COVID-19 vaccine manufacturers in the US have refused to share vaccine samples for research purposes, creating an access issue with the potential to delay comparator studies, follow-on research, and new vaccine / drug development. [read post]
17 Oct 2022, 9:00 am
By Aparajita Lath The Supreme Court of India recently ruled that all women, whether married or not, have equal rights to access abortion up to 24 weeks of gestation, in compliance with the provisions of the Medical Termination of Pregnancy Act, 1971 (MTP Act). [read post]
7 Apr 2023, 7:09 am
By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. [read post]
6 Jul 2023, 6:11 am
By Aparajita Lath Amid ongoing patent disputes over the mRNA platform, a significant scientific question remains unanswered: whether mRNA itself even is patent-eligible. [read post]
